Navigation Links
The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease
Date:11/10/2008

MONTREAL, Nov. 10 /PRNewswire/ -- Montreal Heart Institute Research Centre Director Dr. Jean-Claude Tardif presented yesterday results from a clinical trial demonstrating that VIA-2291, an investigational drug being developed by VIA Pharmaceuticals, Inc., significantly inhibited production of leukotrienes, proposed mediators of vascular inflammation, in patients with serious heart disease. VIA-2291 was well-tolerated with no serious adverse events attributed to the drug. The study was presented in a Special Session at the American Heart Association 2008 Scientific Sessions in New Orleans, Louisiana.

The study of VIA-2291 was designed to establish optimal dosing and safety data in patients with acute coronary syndromes (ACS), who recently had a heart attack or unstable angina. 191 patients were treated once daily for 12 weeks with one of three dose levels of VIA-2291 or placebo. A sub-study of patients continued for an additional 12 weeks of treatment.

Cardiologists have several therapies that help reduce heart disease risk factors, but none that specifically target inflammation, an underlying cause of atherosclerosis, which leads to major adverse cardiac events (MACE), including heart attack and stroke.

VIA-2291 is designed to be a selective and reversible inhibitor of 5-LO, a key enzyme in the biosynthesis of leukotrienes, that are important mediators of inflammation believed to be involved in the development and progression of atherosclerosis.

"VIA-2291 has the potential to be the first drug to specifically target one cardiovascular inflammatory pathway," said Dr. Jean-Claude Tardif, the VIA-2291 ACS trial's principal investigator, director of the Montreal Heart Institute Research Centre and professor of medicine at the Universite de Montreal. "These data support further clinical development of this drug, including larger outcome trials."

Study Results

The trial demonstrated a statistically significant, dose-depende
'/>"/>

SOURCE Montreal Heart Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Chindex International Inc. Reports Second Quarter FY 2009 Financial Results
2. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
3. MGT Capital Investments Reports Third Quarter 2008 Financial Results and Provides Update on Recent Developments
4. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
5. Ellex Announces Six-Month Results on Retina Regeneration Therapy
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
7. InfoLogix to Report Third Quarter Financial Results on November 10, 2008
8. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
9. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
10. Fraxel(R) Laser Systems Shown to Provide Superior Results Compared to Pseudo Fractional Laser Technologies
11. NutraCea Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 Dr. Myo Nwe is ... Loss Diet of the Future” and co-founder of the Ace ... book, Dr. Nwe takes a broad look at the industry ... up under scientific scrutiny. On film and in television shows, ... mostly toward the social aspects and played for basic laughs, ...
(Date:12/17/2014)... WI (PRWEB) December 17, 2014 In ... Administrators and its Argus Claim Review division have ... of the most common ways savings are achieved on ... (TPA) attributes millions of dollars in savings to Argus ... in 2013. , As explained by Tom Doney, Cypress ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... diseases, one worrisome phenomenon is when an illness that originated ... known as zoonosis -- is not uncommon and keeps researchers ... animal-borne disease might make inroads into the human population. ... and the culprits in this case were guinea pigs. More ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... health, but a growing body of evidence shows the ancient ... In fact, the benefits were similar to those of ... Chu, a doctoral candidate at Harvard University,s Health Policy Program ... that people randomly assigned to take yoga classes saw improvements ...
(Date:12/15/2014)... December 15, 2014 Main Street Dental ... is weighing in on a new study providing evidence ... the oral hygiene of children. , Sufficient enough evidence ... such as pop or juice drinks, with the onset ... however, is whether drinks listed as 100% fruit juice, ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... ,Long shifts done by doctors in the hospitals results// in ... and well-trained doctors. ,An U.S study by Harvard ... long shifts without rest have an increased risk (300 per ... be prevented. ,The study was based on ...
... Here is a new dilemma for parents who have ... claim that having younger siblings could// actually raise the chances of ... decreases in the chronological order of the children in the family. ... from Sweden that looked into case sheets of over 13,600 brain ...
... being called a novel finding, researchers using brain scans ... sensory conversion disorder, better known as// hysteria. The study’s ... an unexplained neurological disorder in which a patient complains ... with them. ,The study involved three ...
... with obstructive sleep apnea (OSA) may improve their memory ... study shows that the majority of patients// with OSA, ... performance after 3 months of optimal CPAP use. The ... CPAP adherence. Patients who used CPAP for at least ...
... to a report, San Mateo Seniors quarantine 3 more medical ... reported more this year than the// past. ,San ... outbreak, which has already sickened dozens of people in a ... ill. The doctors added that the outbreak is being ...
... experimental antiretroviral drug designated "MK-0518" rapidly achieves sharp reductions ... the prospect of single-//drug treatment for patients with HIV ... out by further studies, "MK-0518 should clearly be a ... persons infected with HIV-1," concludes the new study, led ...
Cached Medicine News:Health News:Memory Improves After Sleep Apnea Therapy 2Health News:Quarantine Hits 3 More Hospitals In San Mateo 2Health News:New Drug Offers Promise as Single Treatment for HIV 2
(Date:12/15/2014)... , December 15, 2014 Investor-Edge has ... ZGNX ), Eli Lilly and Company (NYSE: ... (NYSE: SNY ), and Novartis AG (NYSE: ... be accessed at: http://investor-edge.com/register . On Friday, ... 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish ...
(Date:12/15/2014)... and BOSTON , December 15, 2014 ... structure-guided drug discovery and development company, is pleased to ... the United States relating to its ... in the US significantly strengthens the global patent estate ... markets. The suite of patents recently granted ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... InterMune, Inc. (Nasdaq: ITMN ) today ... development program for pirfenidone and idiopathic pulmonary fibrosis (IPF) ... European Respiratory Society (ERS), to be held September 18-22 ... Executive Officer and President of InterMune, said, "We are ...
... Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin ... announced today that its President and Chief Executive Officer ... highlighting recent developments at the Rodman & Renshaw 12th ... will take place on Wednesday, September 15, 2010 at ...
Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 2Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: